The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model
Authors:
- 16 February 2016
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 164 (4) , 236-243
Abstract
Mammography trials, which are the primary sources of evidence for screening benefit, were conducted decades ago. Whether advances in systemic therapies have rendered previously observed benefits of screening less significant is unknown. To compare the outcomes of breast cancer screening trials had they been conducted using contemporary systemic treatments with outcomes of trials conducted with previously used treatments. Computer simulation model of 3 virtual screening trials with similar reductions in advanced-stage cancer cases but reflecting treatment patterns in 1975 (prechemotherapy era), 1999, or 2015 (treatment according to receptor status). Meta-analyses of screening and treatment trials; study of dissemination of primary systemic treatments; SEER (Surveillance, Epidemiology, and End Results) registry. U.S. women aged 50 to 74 years. 10 and 25 years. Population. Mammography, chemotherapy, tamoxifen, aromatase inhibitors, and trastuzumab. Breast cancer mortality rate ratio (MRR) and absolute risk reduction (ARR) obtained by the difference in cumulative breast cancer mortality between control and screening groups. At 10 years, screening in a 1975 trial yielded an MRR of 90% and an ARR of 5 deaths per 10 000 women. A 2015 screening trial yielded a 10-year MRR of 90% and an ARR of 3 deaths per 10 000 women. Greater reductions in advanced-stage disease yielded a greater screening effect, but MRRs remained similar across trials. However, ARRs were consistently lower under contemporary treatments. When contemporary treatments were available only for early-stage cases, the MRR was 88%. Disease models simplify reality and cannot capture all breast cancer subtypes. Advances in systemic therapies for breast cancer have not substantively reduced the relative benefits of screening but have likely reduced the absolute benefits because of their positive effect on breast cancer survival. University of Washington and National Cancer Institute.Keywords
This publication has 38 references indexed in Scilit:
- The benefits and harms of breast cancer screening: an independent reviewBritish Journal of Cancer, 2013
- Personalized oncology: Recent advances and future challengesMetabolism, 2013
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trialsThe Lancet, 2012
- How Does Early Detection by Screening Affect Disease Progression?Medical Decision Making, 2011
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus TamoxifenJournal of Clinical Oncology, 2010
- Advanced Breast Cancer and Breast Cancer Mortality in Randomized Controlled Trials on Mammography ScreeningJournal of Clinical Oncology, 2009
- Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assaysThe Breast, 2009
- Effect of Screening and Adjuvant Therapy on Mortality from Breast CancerNew England Journal of Medicine, 2005
- Biomarkers in Cancer Staging, Prognosis and Treatment SelectionNature Reviews Cancer, 2005
- Modeling the impact of the decline in distant stage disease on prostate carcinoma mortality ratesCancer, 2002